For Immediate Release
For more information contact:
Feinstein Kean Healthcare
JOHN HANCOCK'S LONG TERM CARE INSURANCE BUSINESS TO LAUNCH PARTNERSHIP WITH THE ACCELERATED CURE PROJECT
BOSTON, (January 11, 2005) - John Hancock's Long Term Care Insurance business unit today announced a partnership with the Accelerated Cure Project for Multiple Sclerosis, a Boston-based national nonprofit organization dedicated to curing Multiple Sclerosis (MS) by determining its causes. The partnership, which will be managed through John Hancock's Long Term Care (LTC) Community Service Program, will include a financial grant of $50,000 in addition to significant volunteer engagements, marketing and public relations efforts. Previously called the Boston Cure Project, the organization has grown significantly over the past five years and will be expanding throughout the country under the name Accelerated Cure Project for Multiple Sclerosis.
"We are excited to partner with John Hancock as we are always looking for ways to work with businesses who want to make an impact in the community," said Art Mellor, president and CEO, of the Accelerated Cure Project. "This partnership is one of the first major components in our Accelerated Cure Project campaign. The relationship will offer us additional opportunities to search for the causes that will lead to the cure for Multiple Sclerosis."
As part of the agreement, Jim O'Brien, vice president, LTC Systems, will join Accelerated Cure Project's board of directors. In addition, John Hancock will also provide Boston Marathon numbers to the Accelerated Cure Project so they can be used in fundraising and community involvement activities.
"We're excited about this partnership since it will provide John Hancock Long Term Care associates with the opportunity to offer their time and expertise to the Accelerated Cure Project," said Michele Van Leer, executive vice president, John Hancock Long Term Care Insurance. "This collaboration will allow us to extend our presence in the communities in which we work, while gaining a better understanding of our customers. We're proud to be able to play a role in finding a cure for one of the diseases that many of our clients struggle with on a daily basis."
John Hancock's LTC Community Service Program is a unique initiative which has arisen from the LTCI business unit's desire to participate in community outreach programs. Through the program, the LTC department has the opportunity to extend its presence as a business unit on a national and local level in the communities in which it works. In addition to partnering nationally with the Accelerated Cure Project, it has focused on intergenerational community projects in Boston, Milwaukee and Avon, CT.
About John Hancock and Manulife Financial
John Hancock is a division of Manulife Financial, a leading Canadian-based financial services group serving millions of customers in 19 countries and territories worldwide. Operating as Manulife Financial in Canada and most of Asia, and primarily through John Hancock in the United States, the Company offers clients a diverse range of financial protection products and wealth management services through its extensive network of employees, agents and distribution partners. Funds under management by Manulife Financial and its subsidiaries were Cdn$346 billion (US$274 billion) as at September 30, 2004. Manulife Financial Corporation trades as 'MFC' on the TSX, NYSE and PSE, and under '0945' on the SEHK. Manulife Financial can be found on the Internet at www.manulife.com
The John Hancock Division, through its insurance companies, comprises one of the largest life insurers in the United States. John Hancock today offers a broad range of financial products and services, including whole life, term life, variable life, and universal life insurance, as well as college savings products, fixed and variable annuities, long-term care insurance, mutual funds and various forms of business insurance.
About Accelerated Cure Project
Accelerated Cure Project for MS (ACP) is a nonprofit organization whose mission is to accelerate efforts toward a cure for multiple sclerosis (MS) by rapidly advancing research that determines its causes and mechanisms. We provide biomedical researchers with resources that catalyze open scientific collaboration and enable them to explore their novel research ideas rapidly and cost-efficiently. ACP’s strategic initiatives include the Multiple Sclerosis Discovery Forum and the ACP Repository, a large-scale collection of highly-characterized biosamples available to scientists at any organization conducting research that contributes to our mission. All results generated through analysis of Repository samples and data are contributed back to the ACP Repository Database, resulting in an increasingly valuable and comprehensive information resource that can be analyzed to reveal new insights about MS. To date, ACP has enrolled almost 3,000 participants into the Repository through a network of 10 MS clinical centers across the United States. The samples provided by people with MS and related disorders have supported more than 60 research studies worldwide and generated more than 150 million returned data points.
About Multiple Sclerosis
Multiple Sclerosis is a chronic demyelinating disorder of the central nervous system that often results in severe disability including the inability to walk, blindness, cognitive dysfunction, extreme fatigue, and other serious symptoms. MS affects more than 400,000 people in the US and two million individuals worldwide. The disorder occurs twice as often in women as in men. What causes MS is undetermined and no cure has yet been developed.